Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of Action of Seltorexant in MDD
NCT03374475Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of seltorexant in major depressive disorder (MDD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Hamilton Rating Scale for Depression-17 at Day 57, Hamilton Rating Scale for Depression-17 Sleep Item-Adjusted at Day 57 and 2 more. Started Jan 2018; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03374475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374475.